A University of Cambridge spin-out company developing a new therapy for haemophilia
ApcinteX is seeking to disrupt the $10 billion haemophilia market by developing a drug that can be used in all patients, regardless of the type of haemophilia. This novel treatment is based on the work of Professor Jim Huntington (Cambridge Institute for Medical Research) and Dr Trevor Baglin (Cambridge University Hospitals), world-renowned experts in blood clotting disorders.
400,000 individuals in the world are affected by haemophilia
a genetic disorder that causes uncontrolled bleeding
SerpinPC inhibits APC, which degrades the complex that makes thrombin.